Company Analysis
Sign in

Pulse Biosciences, Inc (PLSE)

Nasdaq: PLSE · Surgical & Medical Instruments & Apparatus · Hayward, CA · filing with the SEC since 2014
Full chart Alerts Compare
Grade3.3
◀ Past 2.4● Present 2.8▶ Future 4.7
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Pulse Biosciences, Inc

Nine metrics read from its own filings, by tense
Headline grade
3.3/10
◀ Past2.430% of the headline
● Present2.840% of the headline
▶ Future4.730% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.4/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
3.8/10

Has it survived what it has been through?

3 warning events since 2017; the latest 2024-08-15.

weight 33% of this tense · 38th percentile among 121 sector filers · read for itself

From the record

Pulse Biosciences, Inc's filings since 2017 show 3 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2018-07-31); an auditor change (8-K item 4.01, the latest 2018-04-11); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2024-08-15) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
0.9/10

What has it actually done, year after year?

6 filed years; profitable in 0 of 6.

weight 45% of this tense · 9th percentile among 105 sector filers · read for its customers

From the record

Pulse Biosciences, Inc's 6 filed years say what it did: it rose in 0 of 2 years; the deepest fall was 100% from fiscal 2021 to fiscal 2023; net income was positive in 0 of 6 of those years (its annual reports).

What it rests on

  • the share of years revenue rosebottom 2% of its family
  • the share of filed years with a profitbottom 23% of its family
  • the deepest fall from a revenue peak100.0%bottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
3.5/10

How has it treated the people who own it?

SI estimate 3.5/10, confidence 35 of 100 (one part).

weight 22% of this tense · 35th percentile among 120 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 35% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 120 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Pulse Biosciences, Inc's shareholder treatment is put at 3.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 35% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.8/1040% of the headline grade · 3 of 3 filed

Financial health

as filed
4.2/10

Is it financially healthy right now?

ROE -90%: lost 90¢ per shareholder dollar. Leverage 15%: owes 15¢ per asset dollar.

weight 45% of this tense · 42nd percentile among 120 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Pulse Biosciences, Inc lost about 90 cents for every dollar of shareholders' money, and gross profitability: its products earned less than nothing, about minus 0 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 15 cents per dollar of assets, and net share issuance: its share count grew 15.4% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 12% of its family
  • return on equitybottom 33% of its family
  • gross profit against assetsbottom 3% of its family
  • the share count against the year beforebottom 44% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
0.6/10

How strong is its position in its industry?

bottom 6% of 109 in its family; net margin -20794.6%.

weight 33% of this tense · 6th percentile among 109 sector filers · read for its customers

From the record

Pulse Biosciences, Inc's standing among 109 graded names in its industry family: revenue of $350 thousand in fiscal 2025 ranks in the bottom 8% by size; a net margin of -20794.6% ranks in the bottom 2%; revenue growth of -20.6% a year over the last 3 filed years ranks in the bottom 8% (its annual reports).

What it rests on

  • revenue against the family$350,000bottom 8% of its family
  • net margin-20794.6%bottom 2% of its family
  • three-year revenue growth-20.6%bottom 8% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
3.1/10

What are the people in charge doing?

bottom 31% of 91 in its family for leadership; chief executive since 2025.

weight 22% of this tense · 31st percentile among 91 sector filers · read for its shareholders

From the record

Pulse Biosciences, Inc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Laviolette, Paul A (Chief Executive Officer, as filed), filing under that title since 2025-01-13, 1.8 years (bottom 30% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 5.5 years (top 49%); 12 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 11%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge12 in three years among 10 peoplebottom 11% of its family
  • the median years the people in charge have filed5.5 yearstop 49% of its family
  • the chief executive's years on the record1.8 yearsbottom 30% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.7/1030% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed
5.0/10

How much room does it have to grow?

top 50% of 104 in its family for room to expand.

weight 45% of this tense · 50th percentile among 104 sector filers · read for itself

From the record

Pulse Biosciences, Inc's room to grow, from the newest filed statements (fiscal 2025): cash of $81 million against no long-term debt tagged leaves 85.4% of its assets as net cash, top 2% of its family; cash from operations less capital spending is -15553.4% of revenue (bottom 1%); a gross margin of -54% (bottom 2%); research spending of 12777.4% of revenue (top 1%) (its annual report).

What it rests on

  • cash less debt against assets85.4%top 2% of its family
  • cash from operations less capital spending against revenue-15553.4%bottom 1% of its family
  • gross margin-54.0%bottom 2% of its family
  • research spending against revenue12777.4%top 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
6.3/10

What could actually drive growth from here?

top 37% of 105 in its family for growth drivers.

weight 33% of this tense · 63rd percentile among 105 sector filers · read for its customers

From the record

Pulse Biosciences, Inc's growth drivers, from the filed years to fiscal 2025: research spending grew 29% a year (top 17%); capital spending grew -7.7% a year (bottom 43%) (its annual reports). Pulse Biosciences, Inc tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth of research spending29.0%top 17% of its family
  • three-year growth of capital spending-7.7%bottom 43% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
1.8/10

Did its newest year beat what its own record pointed to?

SI estimate 1.8/10, confidence 35 of 100 (one part).

weight 22% of this tense · 18th percentile among 92 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, net income against the prior three years' average, which ranks in the bottom 18% of 92 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
one part: net income against the prior three years' average, the one part on file, ranked among 92 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Pulse Biosciences, Inc's expectations vs reality is put at 1.8 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the bottom 18% of 92 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton PLSE · research, not advice